Neoplasm Risk in Rheumatic Diseases Has No Correlation With Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs Usage-A Population-Based Nested Case-Control Study

doi:10.3389/fmed.2020.00473

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24620

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24620

Title:	Neoplasm Risk in Rheumatic Diseases Has No Correlation With Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs Usage-A Population-Based Nested Case-Control Study
Authors:	Cai, SZ;Perng, WT;Huang, JY;Chiou, JY;Dong, LL;Wei, JC
Keywords:	neoplasm risks;rheumatic diseases;nested case-control study;population based;disease-modyfying anti-rheumatic drugs
Date:	2020
Issue Date:	2022-08-09T08:05:19Z (UTC)
Publisher:	FRONTIERS MEDIA SA
Abstract:	Objectives:To investigate whether there is an elevated neoplasm risk in patients with rheumatic diseases treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Methods:A population-based nested case-control study was performed by retrieving all patients newly diagnosed with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and psoriatic arthritis (PsA) or psoriasis vulgaris (PsO) from the 2000 Longitudinal Health Insurance Database (LHID 2000) in Taiwan. Two hundred and sixty-one patients with neoplasm from 1997 to 2013 were enrolled in this study, and controls were matched in a 1:1 ratio with age, sex, and year of enrollment. Composition of demographic indices, comorbidities, medication usage, and differences in days of prescription of different medications between neoplasm and neoplasm-free (control) groups were compared. Results:Between the control and neoplasm groups, no differences in ratio were observed in the usage of hydroxychloroquine (50.96 vs. 49.04%,p= 0.6616), methotrexate (26.82 vs. 27.59%,p= 0.8441), azathioprine (3.45 vs. 3.07%,p= 0.8052), and cyclophosphamide (1.15 vs. 2.30%,p= 0.3131) from enrollment to index date. Medications within 3 years before the index date in patients that had >= 3 months of comparable duration also showed no difference (hydroxychloroquine: 33.06 vs. 30.25%,p= 0.6404; methotrexate: 20.66 vs. 25.21%,p= 0.4018; azathioprine: 2.48 vs. 2.52%,p= 0.9835; cyclophosphamide: 0.83 vs. 0.84%,p= 0.9906). We also made a subgroup analysis focusing on RA and SLE patients; no difference between control and neoplasm group in both the ratio of usage and days of prescription of hydroxychloroquine, methotrexate, azathioprine, and cyclophosphamide was observed. Conclusion:Neoplasm risk in patients with rheumatic diseases has no correlation with csDMARD usage.
URI:	http://dx.doi.org/10.3389/fmed.2020.00473 https://www.webofscience.com/wos/woscc/full-record/WOS:000570565800001 https://ir.csmu.edu.tw:8080/handle/310902500/24620
Relation:	FRONTIERS IN MEDICINE ,2020 ,v7
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	200	View/Open

Loading...